A new approach to depression

Tue, 08 Oct 2013 16:05:00 +1100

THE AIM
We would like to study the benefits of adding a new treatment for depression to your usual treatment.

THE REASON
It is believed that the symptoms of depression may be partially caused by increased levels of inflammation and oxidative stress (an imbalance in the levels of antioxidants) in the brain.  Minocycline also stimulates the growth and survival of brain cells. There is evidence to suggest that minocycline, a commonly prescribed antibiotic, may have properties that target these factors.  Minocycline may be beneficial by reducing inflammation and oxidative stress and stimulating brain cell growth, which may in turn reduce the symptoms experienced by those with depression.

PERSONS ELIGIBLE FOR THE TRIAL

Anyone who is currently experiencing symptoms of depression.

KEY POINTS FOR PARTICIPANTS

  • The trial will NOT involve any costs.
  • People will continue their usual treatment.
  • The treatment trial will last 3 months.
  • We will meet with you at least 7 times over the course of the trial.
  • The study is located in Melbourne and Geelong

THE RESEARCHERS
This trial is a joint venture between Deakin University and Barwon Health.

CONTACT DETAILS
Persons wishing to take part in the trial can obtain more information from the trial coordinator:

Dr Olivia Dean
Telephone (03) 4215 3300
mino@barwonhealth.org.au


Dr Olivia Dean
Dr Olivia Dean
Deakin Research Commercial
Showcase facts
  • We would like to study the benefits of adding a new treatment for depression to your usual treatment.
More information
Olivia Dean
T: +61342153300
Facebook

Deakin University acknowledges the traditional land owners of present campus sites.

20th August 2012